Clinicohistopathologic profile of patients who underwent Mohs micrographic surgery at the dermatology center of a tertiary hospital in the Philippines from March 2003 to March 2023: A 20-year review
- Author:
Patricia Louise A. Henson-Riola
;
Cynthia C. Tan
- Publication Type:Review
- Keywords: Chart Review
- MeSH: Mohs Micrographic Surgery; Mohs Surgery; Skin Cancer; Skin Neoplasms
- From: Journal of the Philippine Dermatological Society 2024;33(Suppl 1):39-39
- CountryPhilippines
- Language:English
-
Abstract:
BACKGROUND
Mohs micrographic surgery (MMS) is the preferred surgical procedure for non melanoma skin cancers (NMSCs), especially in areas where function and cosmesis are critical. It allows precise removal of the tumor while preserving normal skin tissue.
OBJECTIVESThis study aimed to describe the clinicohistopathologic profile of patients who underwent MMS at the Dermatology Center of the St. Luke’s Medical Center, Quezon City, Philippines (SLMC-QC) from March 2003 to March 2023.
METHODSThis was a descriptive cross-sectional study utilizing a 20-year chart review on all patients who underwent MMS at SLMC-QC from March 2003 to March 2023. Data collected were the following: age, sex, race, clinicopathologic diagnosis, tumor site, pre-operative and post-operative area size, number of MMS stages, type of repair performed, and recurrence, if any.
RESULTSIn 20 years, there were a total of 684 cases done in the Dermatology Center SLMC-QC, and 573 cases with complete data were included. Eighty six percent of patients were over 50 years old. There was a slight male predominance, and most patients were Asians, followed by Caucasians. Basal cell carcinoma was the most common diagnosis followed by squamous cell carcinoma and Bowen’s disease. Majority of the tumors were located on the head and neck. The postoperative defect increased by 2-to-3-fold from the preoperative tumor size in most cases. Most tumors were cleared in 2 stages. The most common type of repair done was flaps, followed by full-thickness skin grafts and primary closures. All primary tumors treated in the center have not recurred within 5 years, bringing the cure rate to 100%.
CONCLUSIONThe clinicohistopathologic profiles of patients in this study are similar to those reported in the literature. No recurrence has been reported in the center and this reflects the effectivity of MMS.